Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMay072015	Fate Therapeutics Reports First Quarter 2015 Financial Results Strategic Research Collaboration Established with Juno Therapeutics to Apply Small Molecule Modulators for Programming CAR and TCR Immunotherapies Additional Data from Ongoing Phase 2 PUMA Study of PROHEMA® Continue to Demonstrate Acceleration of, and Increased Incidence of Early, Neutrophil Read All »	View HTML Fate Therapeutics Reports First Quarter 2015 Financial Results 30.9 KB
Toggle SummaryMay132014	Fate Therapeutics Reports First Quarter 2014 Financial Results Phase 2 PUMA Study of PROHEMA® in Adult Hematologic Malignancies Enrolling Patients Phase 1b PROMPT Study of PROHEMA in Pediatric Hematologic Malignancies Cleared by FDA IND Submission for Study of PROHEMA in Rare Genetic Disorders Expected in 2Q14 SAN DIEGO, May 13, 2014 (GLOBE NEWSWIRE) -- Read All »	View HTML Fate Therapeutics Reports First Quarter 2014 Financial Results 25.2 KB
Toggle SummaryJun282010	Fate Therapeutics Receives Red Herring's North America 100 Award for Advancing Stem Cell Technology and New Medicines San Diego, CA and Ottawa, Canada – Fate Therapeutics, Inc. announced today that the Company received Red Herring’s North America 100 award, a prestigious list honoring the year’s most promising private and innovative companies from the North American business region. Read All »	View HTML Fate Therapeutics Receives Red Herring’s North America 100 Award for Advancing Stem Cell Technology and New Medicines 189.8 KB
Toggle SummarySep262016	Fate Therapeutics Receives FDA Orphan Drug Designation for ProTmune™ in Allogeneic Hematopoietic Cell Transplantation SAN DIEGO, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Read All »	View HTML Fate Therapeutics Receives FDA Orphan Drug Designation for ProTmune™ in Allogeneic Hematopoietic Cell Transplantation 16 KB
Toggle SummaryFeb042010	Fate Therapeutics Receives Allowance of First U.S. Patent for Induced Pluripotent Stem Cell Technology San Diego, CA – Fate Therapeutics, Inc. received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application Number 10/997,146 entitled “Methods for Reprogramming Somatic Cells.” Upon issuance, the patent will cover foundational induced Read All »	View HTML Fate Therapeutics Receives Allowance of First U.S. Patent for Induced Pluripotent Stem Cell Technology 12.6 KB
Toggle SummaryDec072015	Fate Therapeutics Provides Update on Adoptive Immunotherapy Programs for Hematopoietic Cell Transplantation Supportive Interim Data from ProHema® PUMA Study Demonstrate the Therapeutic Potential of Programmed Donor Cells Clinical Development Strategy to Focus on Prevention of Life-Threatening Complications in Mobilized Peripheral Blood HCT ProTmune™ to Advance into Phase 1/2 Clinical Trial for Read All »	View HTML Fate Therapeutics Provides Update on Adoptive Immunotherapy Programs for Hematopoietic Cell Transplantation 27.5 KB
Toggle SummaryDec062020	Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million Cells Deepening of Response Observed with FT596 Retreatment Duration of Response Comparable to FDA-approved Autologous CAR T-cell Therapy for Patients with Partial Response No Read All »	View HTML
Toggle SummaryDec042018	Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting FT500, First-ever iPSC-derived Cell Product Candidate Cleared for U.S. Clinical Investigation by FDA, Featured in Oral Presentation SAN DIEGO , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of Read All »	View HTML
Toggle SummaryApr012019	Fate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting High-Throughput Selection of a Single Gene-Edited iPSC Enables Mass Production of Uniformly Engineered CAR T Cells FT819 Off-the-Shelf CAR19 T-cell Product Candidate Demonstrates Complete Elimination of TCR Expression and Integration of Novel 1XX CAR into TRAC Locus SAN DIEGO, Calif. Read All »	View HTML
Toggle SummaryDec102019	Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting FT819 Exhibits Enhanced Tumor Clearance In Vivo Compared to Primary CAR T Cells in Preclinical Leukemia Model Master Engineered iPSC Line for FT819 Fully Characterized for Complete Elimination of TCR Expression and Integration of Novel 1XX CAR into TRAC Locus with No Evidence of Off-target Effects Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.